BioCardia (NASDAQ:BCDA) Announces Quarterly Earnings Results

BioCardia (NASDAQ:BCDA) announced its quarterly earnings data on Wednesday. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.62, Zacks reports. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. During the same quarter last year, the business earned ($8.19) EPS.

BioCardia Price Performance

Shares of BioCardia stock opened at $2.68 on Friday. BioCardia has a 1 year low of $1.63 and a 1 year high of $6.30. The business has a 50 day moving average price of $2.45 and a 200 day moving average price of $2.41. The company has a market capitalization of $12.29 million, a P/E ratio of -0.64 and a beta of 1.28.

Insider Buying and Selling at BioCardia

In related news, Director Simon H. Stertzer acquired 22,753 shares of BioCardia stock in a transaction dated Monday, March 3rd. The shares were acquired at an average cost of $2.30 per share, for a total transaction of $52,331.90. Following the completion of the transaction, the director now directly owns 40,602 shares of the company’s stock, valued at $93,384.60. The trade was a 127.47 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have purchased 25,353 shares of company stock worth $58,525. 20.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BCDA shares. Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.